Vai al contenuto principale
Coronavirus: aggiornamenti per la comunità universitaria / Coronavirus: updates for UniTo Community

Master II level- Stem cells in Regenerative Medicine and Cell Factory Management

a.y. 2020/2021

Prof.ssa Fiorella Altruda

Decreto Rettorale di istituzione n. 2361 del 9/7/2020


The field of regenerative medicine has considerably expanded with important investments by pharmaceutical companies both on research and - above all - in the development of clinical applications. Whilst approved and available clinical applications in patients are limited to some areas due to the complexity and length of the authorization process, experimental and preclinical research offer great potential for the development of new applications in the near future.

To accelerate the implementation of new opportunities that are emerging (and that will arise in the coming years), collaboration between research teams of public and private sectors is essential and must involve industries, clinicians, research laboratories, cell factories and control and monitoring bodies. Each of these sectors requires dedicated specialized personnel.

The staff employed in regenerative medicine activities need a highly specific and qualified preparation, which - according to all operators in the chain - goes beyond the university studies. Indeed, young graduates are not sufficiently trained to understand and know how to move within the chain that leads from the laboratory to the patient's bed. In particular, there is urgent need to prepare professionals with knowledge of the biological properties of stem cells and regenerating tissues to the experimental design of a new advanced protocol; use of biocompatible materials for the production of therapeutic grade cells; management and certification of a cell factory establishment for the use of cellular products in patient-specific therapies.

The course is aimed at young people with a Master's degree in biological, chemical, pharmaceutical, medical and health sectors. Undergraduates of the master's degrees listed below are also admitted on condition that the degree is achieved by 31 December 2020. It is not necessary to have any professional qualification.

In particular, students with the following Master degrees can be admitted to the II level Master course:

  • Pharmacy, Industrial Pharmacy and Pharmaceutical Chemistry
  • Biomedical Engineering
  • Medicine and Surgery
  • Veterinary Medicine
  • Medical, Veterinary and Pharmaceutical Biotechnology
  • Industrial Biotechnology
  • Biology

The aim of this Master Course is to prepare qualified professionals in the field of applied pharmacology and biotechnology. The training objectives are multidisciplinary and cover all aspects of regenerative medicine.

Students will learn and apply the acquired knowledge on stem cells, endogenous and experimental tissue regeneration, cutting-edge technologies and their interface with molecular therapies, stem technologies, tissue engineering and the use of innovative biomaterials, sampling methods, expansion, culture, manipulation, monitoring, conservation and traceability of human cells, the regulatory needs regarding these emerging technologies, the regulations in the clinical / pharmaceutical field as well as the management of the Quality System according to current regulations in the field of cell manipulation and human tissues. The topic of technological transfer in biotechnology in public and private institutions will also be addressed.

The course has a duration of 1 year and comprises 7 thematic modules, relating to the tissues subject to regeneration in the medical field, and 1 module on management and administration in healthcare. The course includes an ample practical internship and 5 daily workshops on transversal topics  

The master is divided into the following macro-areas:

  • Tissue regeneration in the medical field;
  • Multi-layered epithelia;
  • Mesenchymal tissues;
  • The hematopoietic system and stem cells;
  • The liver tissue;
  • The skeletal and cardiac muscle tissue;
  • The Cell Factory and Advanced Therapies;
  • Management, Administration, Information in the Healthcare Structure;
  • Seminar 1: Gene and cellular therapies: state of the art;
  • Seminar 2: Ex vivo genetic manipulation - gene re-expression, gene editing, reprogramming;
  • Seminar 3: Tissue Manipulation and Bio-Banking for Advanced Therapies and Traceability Technology;
  • Seminar 4: Drug registration procedures, including for advanced therapies;
  • Seminar 5: The market, employment opportunities, pharmaceutical industrial trends.
  • Practical stages: in organizations companies, hospitals and cell factories (also in locations other than the DBMSS).

  • Pr. Fiorella Altruda Director of Master program – Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Pr. Giorgio Roberto Merlo Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Pr. Emanuela Tolosano Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Pr. Mario Boccadoro Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Dr. Marta Coscia Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Pr. Renato Romagnoli Dept. of Surgical Sciences, University of Turin
  • Pr. Michele de Luca  University of Modena-Reggio Emilia
  • Pr. Barbara Zavan Dept. of Biomedical Sciences, University of Padova
  • Dr.Valentina Fonsato- Cell Factory, Dept. of Molecular Biotechnology and Health Sciences, MBC, University of Turin
  • Dr. Sharmila Fagoonee, Institute of Biostructure and Bioimaging (CNR), MBC, Turin

  • Students will acquire knowledge and skills in the field of scientific and technological innovation and technology transfer; they will also be able to manage and design biotechnological and pharmaceutical and regenerative medicine methodologies, in order to:
  • Students will learn those key aspects linking the world of research, clinic, business and industries
  • Students will simulate the development and testing of innovative pharmacological products including gene therapy, cell therapy and nano-biotechnology) of particular relevance to therapy for human diseases
  • Students will develop strategies for large-scale bio-productions
  • Students will design and produce patents in the bio-medicine field
  • Student will be trained and practice business development in the field of emerging biomedical technologies

Moreover, students will be exposed to:

  • Employment growth in the area of ​​research and development of enterprises and employment growth also through enterprise spin-offs
  • Scientific advice and dissemination

Upon completion of the Master program, the participants will be qualified for positions at local health companies, hospitals, IRCCS, polyclinics, private health companies, research and training centers operating in the regenerative medicine sector. In addition, the participants will be able to carry out research in various disciplinary areas related to the use of stem cells in basic research. Companies and subjects involved in the development of this Master program may request qualified personnel stemming from this course; companies, hospitals and cell factories need to hire trained staff to be able to expand their projects and regenerative medicine-related activities.

The student will receive credentials to access the telematic platform, where he/she will be able to find all the teaching materials regarding the STEM-MED Master Course:

  • online video lessons;
  • chat active during live online lessons;
  • virtual plaza where students can meet and discuss with the teachers;
  • specifically-prepared paper documentation;
  • bibliography;
  • reference links recommended by the teacher for further information;
  • evaluation test;
  • specific practical stages and exercises.

For the practical sessions, presence is necessary but in very small groups (1 or 2 people);

A final face-to-face test is scheduled.

Due to COVID-19 emergency, some lessons may be followed through distance learning

The evaluation strategy will be as follows:

Self-evaluation: Participants will be provided with tools to constantly test their learning and provide feedback on the learning progress.

Knowledge and skills acquired during the program will be evaluated through specific tasks and exams. Participants will be asked to complete and submit the required tasks and tests for each module and get the tutor's evaluation before the prescribed deadlines. The scientific committee should approve the final thesis work.

Teachers, while considering the student’s interest, will guide practical placements.

Monitoring and evaluation of the program.

The Master coordinators will constantly monitor the program and participants’ specific requests and introduce changes if necessary. At the end of the program, participants will express their opinions on topics, activities, administration and organization of the course in a final evaluation form.

  • Registration procedure registration opening: 30 july 2020
  • Registration deadline: 30 september 2020

The application for registration has the sole purpose of admitting to the selections.

In order to be admitted to the selection, enrollment on the University portal must start from 9.30 on 30 July 2020 and before 15.00 on 30 September 2020. Please follow the registration procedures on the University portal and the Master's selections and access

Documents to be attached

To complete the registration procedure for the Master's selections, it is necessary to send to the Master secretariat at

  1. confirmation of the online submission of the application for enrollment in the selections via the University Portal (indicating the name of the Master for which enrollment was made)
  2. curriculum vitae indicating: 1)knowledge of cellular cultures 2) laboratory experience 3) level  english language.

The staff of the master is available for information:

The data collected during the pre-accession procedure will be used pursuant to Art. 13 of Legislative Decree 196/03.

  • Selection procedure results 15th October 2020
  • Enrolment from 19th October 2020 9:30 to 30 October 15:30
  • Master begins in November 2020

The registration fee for the 2020/2021 edition is 2,500 euros

The fee payment will take place in two installments:

  • First installment: 1250 euros upon Registration
  • Second installment: 1250 euros by 30th March 2021

It is possible to register for the single module (modules 1 to 7) or for all modules and seminars as auditors, without attending the practical internship, and without undertaking evaluations and final exam


  • Module 1: Tissue regeneration in medicine: 300 Euro (inclusive of all submodules)

  • Module 2: Pluristratified epithelia: 300 Euro (inclusive of all submodules)

  • Module 3: Mesenchymal tissues: 300 Euro (inclusive of all submodules)

  • Module 4: The hematopoietic system and stem cells: 300 Euro (inclusive of all submodules)

  • Module 5: Hepatic tissue: 300 Euro (inclusive of all submodules)

  • Module 6: Skeletal and cardiac muscle tissue: 300 Euro (inclusive of all submodules)

  • Module 7: Cell Factory and advanced therapy (all 3 submodules) and all seminars: 600 Euro

  • Module 8: Management, Amministration and Information in the health facility: free of charge if registered to one of the above modules

All modules (without attending the practical internship, and without undertaking evaluations and final exam): 1000 Euros

  • minimum: 7 places
  • maximum: 12 places

Centro Interdipartimentale per le Biotecnologie Molecolari (MBC), Via Nizza 52, 10126 Torino

  • Director of the Master Program- Pr. Fiorella Altruda –e-mail: 
  • Coordinator: Pr. Giorgio Roberto Merlo – e-mail:
  • Coordinator: Dr. Sharmila Fagoonee – e-mail:
  • Academic Office - Dr. Cornelia Di Gaetano– e-mail:
  • Info:


Last update: 17/03/2021 12:33
Non cliccare qui!